Pacira BioSciences (PCRX) Operating Expenses (2010 - 2026)

Pacira BioSciences' Operating Expenses history runs 17 years deep, the most recent figure standing at $170.5 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 2.12% year-over-year to $170.5 million in Q1 2026; TTM through Mar 2026 was $710.8 million, a 9.73% decrease from a year earlier, with the FY2025 full-year figure at $707.2 million, down 8.67% from the prior year.
• Operating Expenses declined to $170.5 million in Q1 2026 per PCRX's latest filing, from $194.5 million in the prior quarter.
• Across five years, Operating Expenses topped out at $308.1 million in Q3 2024 and bottomed at $129.6 million in Q2 2023.
• The 5-year median for Operating Expenses is $162.5 million (2024), against an average of $167.4 million.
• Across the five-year window, Operating Expenses jumped 110.73% in 2024 and tumbled 43.8% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $181.8 million in 2022, then dropped by 18.57% to $148.1 million in 2023, then grew by 9.77% to $162.5 million in 2024, then advanced by 19.68% to $194.5 million in 2025, then declined by 12.37% to $170.5 million in 2026.
• Per Business Quant, the three latest PCRX Operating Expenses figures stand at $170.5 million (Q1 2026), $194.5 million (Q4 2025), and $173.2 million (Q3 2025).